3SBio Inc. Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap Index

SHENYANG, China, Aug. 17, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio") today announced that effective September 14, 2015, it will be added as a constituent of the Hang Seng LargeCap & MidCap Index according to a press release issued by Hang Seng Indexes Company Limited ("Hang Seng") on August 14, 2015. The Hang Seng LargeCap & MidCap Index is a sub-index of the Hang Seng Composite Index, a comprehensive benchmark index covering the top 95% of the total market capitalization of companies listed on the Main Board of the Hong Kong Stock Exchange. As of August 14, 2015, 3SBio's market capitalization was approximately HKD 21.9 billion, ranking 189 out of 1,839 listed companies.

"We believe that our inclusion in the Hang Seng benchmark index will create more awareness of 3SBio's recent successful initial public offering on the Hong Kong Stock Exchange," Dr. Jing Lou, chairman and chief executive officer of 3SBio, said in a statement.

About 3SBio Inc.

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four New Drug Application ("NDAs") for biological medicines, including TPIAO, the first rhTPO product commercialized worldwide.

3SBio has over 20 pipeline products with 14 of them developed as innovative class 1 products in China. Pipeline candidates include SSS07, an anti-TNF monoclonal antibody with a Phase I trial underway in China for the treatment of rheumatoid arthritis; NuPIAO/SSS06, a long-acting erythropoiesis-stimulating agent(ESA) for anemia associated with renal failure or chemotherapy and peri-operative blood cell mobilization which has entered into Phase I clinical trials in China; Uricase PEG-20/SSS11, a modified pegylated recombinant uricase from Candida utilis for the treatment of refractory gout and tumor lysis syndrome which has completed US Phase I trials; Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for treating acute leukemia; and Tanibirumab/SSS23, an anti-VEGFR2 monoclonal antibody for treating solid tumors.

A new state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards. In December 2014, 3SBio acquired Sirton Pharmaceuticals SpA, a European contract manufacturer and Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd, a Shenzhen-based manufacturer of biopharmaceuticals. In July 2015, 3SBio acquired Zhejiang Wansheng Pharmaceutical Co., Ltd., adding small-molecule R&D and manufacturing capabilities. 

3SBio is China's leading specialist in nephrology and oncology supportive care with more than 600 sales professionals, covering over 3,000 hospitals in key cities supported by a nationwide network of 120 distributors and logistics providers. EPIAO has been the top selling rhEPO product in China since 2002 with a market share over 40%.

3SBio trades on the Stock Exchange of Hong Kong under code 1530.

Please visit www.3sbio.com for additional information.